Ferring Pharmaceuticals and North Zealand University Hospital mark first milestone in innovative IBD collaboration
-Ferring Pharmaceuticals and North Zealand University Hospital (Nordsjællands Hospital) yesterday formally inaugurated…
Ferring Pharmaceuticals Acquires Exclusive Licensing Rights to Condoliase from Seikagaku Corporation
-Ferring Pharmaceuticals announced today that it has signed an agreement with Seikagaku Corporation granting Ferring the exclusive worldwide rights…
Ferring announces Phase 3 data for investigational human recombinant FSH with individualised dosing regimen at the 32nd Annual Meeting of ESHRE®
-Data from the Phase 3 ESTHER trials (Evidence-based Stimulation Trial with Human recombinant follicle-stimulating hormone…
Ferring Pharmaceuticals announces approval of new tailored dosing regimen in the PICOPREP® (sodium picosulfate, magnesium oxide, citric acid) label in MRP countries in Europe
-Ferring Pharmaceuticals has successfully finalised a Mutual…
Ferring demonstrates commitment to R&D investment through expanded Innovation Grants Program
-The Ferring Innovation Grants Program, which is now open for applications, has been significantly expanded as part of Ferring’s continued commitment to investing in research and development…
Archives Press release 2016
Archives Press release 2016